These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8162161)

  • 1. Effects of long-term treatment with the gonadotropin-releasing hormone analog nafarelin in patients with non-functioning pituitary adenomas.
    Colombo P; Ambrosi B; Saccomanno K; Bassetti M; Cortelazzi D; Faglia G
    Eur J Endocrinol; 1994 Apr; 130(4):339-45. PubMed ID: 8162161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal response of luteinizing hormone beta subunit to thyrotrophin-releasing hormone in patients with non-functioning pituitary adenoma.
    Gil-del-Alamo P; Pettersson KS; Saccomanno K; Spada A; Faglia G; Beck-Peccoz P
    Clin Endocrinol (Oxf); 1994 Nov; 41(5):661-6. PubMed ID: 7828356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadotropin and alpha-subunit responses to chronic gonadotropin-releasing hormone analog administration in patients with glycoprotein hormone-secreting pituitary tumors.
    Klibanski A; Jameson JL; Biller BM; Crowley WF; Zervas NT; Rivier J; Vale WW; Bikkal H
    J Clin Endocrinol Metab; 1989 Jan; 68(1):81-6. PubMed ID: 2535852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of thyrotropin-releasing hormone test, SMS 201-995, and bromocriptine in the diagnosis and treatment of gonadotropin-secreting pituitary adenomas.
    Blanco C; Lucas T; Alcañiz J; Davila N; Serrano P; Barcelò B; Estrada J
    J Endocrinol Invest; 1994 Feb; 17(2):99-104. PubMed ID: 8006339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gonadotropin-releasing hormone agonists are unsuccessful in reducing tumoral gonadotropin secretion in two patients with gonadotropin-secreting pituitary adenomas.
    Sassolas G; Lejeune H; Trouillas J; Forest MG; Claustrat B; Lahlou N; Loras B
    J Clin Endocrinol Metab; 1988 Jul; 67(1):180-5. PubMed ID: 2967850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute hormonal responses to the gonadotropin releasing hormone agonist leuprolide: dose-response studies and comparison to nafarelin--a clinical research center study.
    Rosenfield RL; Perovic N; Ehrmann DA; Barnes RB
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3408-11. PubMed ID: 8784105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new test of combined pituitary-testicular function using the gonadotropin-releasing hormone agonist nafarelin in the differentiation of gonadotropin deficiency from delayed puberty: pilot studies.
    Ehrmann DA; Rosenfield RL; Cuttler L; Burstein S; Cara JF; Levitsky LL
    J Clin Endocrinol Metab; 1989 Nov; 69(5):963-7. PubMed ID: 2529266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of thyrotropin-releasing hormone on gonadotropin and free alpha-subunit secretion in patients with acromegaly and functionless pituitary tumors.
    Popovic V; Damjanovic S
    Thyroid; 1998 Oct; 8(10):935-9. PubMed ID: 9827662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovulation inhibition with nafarelin acetate nasal administration for six months.
    Brenner PF; Shoupe D; Mishell DR
    Contraception; 1985 Dec; 32(6):531-51. PubMed ID: 2936564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas.
    Andersen M; Bjerre P; Schrøder HD; Edal A; Høilund-Carlsen PF; Pedersen PH; Hagen C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):23-30. PubMed ID: 11167922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-related changes in LH bioactivity with intranasal GnRH agonist administration.
    Chiang RS; Barnes RB; Shoupe D; Lobo RA
    Contraception; 1985 Oct; 32(4):347-57. PubMed ID: 2934222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovulation triggering in clomiphene citrate-stimulated cycles: human chorionic gonadotropin versus a gonadotropin releasing hormone agonist.
    Schmidt-Sarosi C; Kaplan DR; Sarosi P; Essig MN; Licciardi FL; Keltz M; Levitz M
    J Assist Reprod Genet; 1995 Mar; 12(3):167-74. PubMed ID: 8520180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of a gonadotrophin-releasing hormone agonist ([D-Ser(But)6]GnRH(1-9)nonapeptide-ethylamide) on gonadotrophin secretion from human pituitary gonadotroph cell adenomas in vitro.
    Daniels M; Newland P; Dunn J; Kendall-Taylor P; White MC
    J Endocrinol; 1988 Sep; 118(3):491-6. PubMed ID: 2460576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resolution of possible paradoxical responses of gonadotropins to thyrotropin-releasing hormone with bromocriptine therapy in a patient with follicle-stimulating hormone-secreting pituitary adenoma.
    Mercado-Asis LB; Yasuda K; Ishizawa M; Ishizuka T; Murayama M; Shimokawa K; Miura K
    Endocrinol Jpn; 1992 Aug; 39(4):401-6. PubMed ID: 1446655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotrophin and free alpha-subunit secretion in patients with acromegaly and clinically non-functioning pituitary tumors: anterior pituitary function and the effect of thyrotrophin-releasing hormone.
    Damjanović SS; Popović VP; Petakov MS; Nikolic-Durović MM; Doknić MZ; Gligorović MS
    J Endocrinol Invest; 1996 Nov; 19(10):663-9. PubMed ID: 9007697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormonal effects of GnRH agonist in the human male: II. Testosterone enhances gonadotrophin suppression induced by GnRH agonist.
    Bhasin S; Heber D; Steiner B; Peterson M; Blaisch B; Campfield LA; Swerdloff RS
    Clin Endocrinol (Oxf); 1984 Feb; 20(2):119-28. PubMed ID: 6232019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Responses to gonadotropin releasing hormone agonist and antagonist administration in patients with gonadotroph cell adenomas.
    Chanson P; Lahlou N; Warnet A; Roger M; Sassolas G; Lubetzi J; Schaison G; Bouchard P
    J Endocrinol Invest; 1994 Feb; 17(2):91-8. PubMed ID: 8006338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gonadotroph adenoma with secondary hypersecretion of testosterone.
    Chamoun R; Layfield L; Couldwell WT
    World Neurosurg; 2013 Dec; 80(6):900.e7-11. PubMed ID: 23201183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired estrogen-induced negative feedback on gonadotropin secretion in patients with gonadotropin-secreting and nonfunctioning pituitary adenomas.
    Lania A; Gangi E; Romoli R; Losa M; Travaglini P; Meringolo D; Ambrosi B; Faglia G; Beck-Peccoz P; Spada A
    Eur J Clin Invest; 2002 May; 32(5):335-40. PubMed ID: 12027873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison between the diagnostic value of gonadotropins, alpha-subunit, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, alpha-subunit-secreting, and gonadotroph pituitary adenomas.
    Nobels FR; Kwekkeboom DJ; Coopmans W; Hoekstra R; De Herder WW; Bouillon R; Lamberts SW
    J Clin Endocrinol Metab; 1993 Sep; 77(3):784-9. PubMed ID: 7690365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.